The Scottish Medicines Consortium has approved Verkazia eye drop emulsion for the treatment of vernal keratoconjunctivitis in children from 4 years of age and adolescents, Santen UK Limited announced in a press release.
Verkazia, which contains 0.1% cyclosporine, targets the underlying cause of inflammation at the surface of the eye.
“The SMC decision to approve Verkazia marks a real turning point for everyone affected by this distressing condition in Scotland, providing, at last, an effective, licensed option which can be used to sustainably control the signs and symptoms of severe VKC,”
Uncategorized